Loading
A phase 3 trial of Pembrolizumab, Carboplatin, Docetaxel and Cisplatin in endometrial cancer, run by Merck Sharp & Dohme LLC, active and no longer recruiting.
Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053) is a phase 3 interventional study registered as NCT04634877 by Merck Sharp & Dohme LLC, with 990 participants enrolled, started 2021-01-10 and due to reach its primary completion in 2026-09-15. Interventions recorded: Pembrolizumab, Carboplatin, Paclitaxel, Placebo for pembrolizumab, Docetaxel and Cisplatin.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Mismatch-repair-deficient endometrial cancer, Docetaxel, Merck & Co. (MSD), Endometrial cancer and the tag pipeline.
Shares Merck & Co. (MSD), Cisplatin, Carboplatin, Pembrolizumab and the tag pipeline.
Shares Merck & Co. (MSD), Cisplatin, Carboplatin, Pembrolizumab and the tag pipeline.
Shares Merck & Co. (MSD), Cisplatin, Carboplatin, Pembrolizumab and the tag pipeline.
Shares Mismatch-repair-deficient endometrial cancer, Endometrial cancer, Carboplatin, Immune checkpoint inhibitors and the tag pipeline.
Shares Merck & Co. (MSD), Endometrial cancer, Carboplatin, Pembrolizumab and the tag pipeline.
Shares Merck & Co. (MSD), Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Merck & Co. (MSD), Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/